Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Fate Therapeutics price target raised to $40 from $34 at Oppenheimer » 07:44
06/10/20
06/10
07:44
06/10/20
07:44
FATE

Fate Therapeutics

$32.70 /

+4.45 (+15.75%)

Oppenheimer analyst…

Oppenheimer analyst Matthew Biegler raised the firm's price target on Fate Therapeutics to $40 from $34 and keeps an Outperform rating on the shares. The analyst notes that Fate has provided updates on its iPSC-derived cell therapy programs in conjunction with an equity financing. The update included preliminary data from the first two lymphoma patients treated with FT596, the company's COVID-19-targeting CARNK, he adds. Biegler believes the results represent an important early proof-of-concept for FT596 and support the disruptive potential of Fate's iPSC-derived cell therapy platform.

ShowHide Related Items >><<
FATE Fate Therapeutics
$32.70 /

+4.45 (+15.75%)

FATE Fate Therapeutics
$32.70 /

+4.45 (+15.75%)

06/09/20 Piper Sandler
Fate Therapeutics price target lowered to $59 from $63 at Piper Sandler
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 H.C. Wainwright
Fate Therapeutics initiated with a Buy at H.C. Wainwright
04/02/20 Piper Sandler
Fate Therapeutics price target raised to $63 from $57 at Piper Sandler
FATE Fate Therapeutics
$32.70 /

+4.45 (+15.75%)

  • 09
    Jun
FATE Fate Therapeutics
$32.70 /

+4.45 (+15.75%)

Recommendations
Fate Therapeutics price target lowered to $59 from $63 at Piper Sandler » 15:46
06/09/20
06/09
15:46
06/09/20
15:46
FATE

Fate Therapeutics

$32.30 /

+4.05 (+14.34%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff lowered the firm's price target on Fate Therapeutics to $59 from $63 to account for dilution after the company issued 6.18M shares at $28.31 for gross proceeds of $175M. Tenthoff, who estimates Fate now has pro forma cash of about $494M, reiterates an Overweight rating on the shares after Fate also announced early FT596 data and updated FT516 and FT500 progress.

ShowHide Related Items >><<
FATE Fate Therapeutics
$32.30 /

+4.05 (+14.34%)

FATE Fate Therapeutics
$32.30 /

+4.05 (+14.34%)

05/13/20
Fly Intel: Top five analyst initiations
05/13/20 H.C. Wainwright
Fate Therapeutics initiated with a Buy at H.C. Wainwright
04/02/20 Piper Sandler
Fate Therapeutics price target raised to $63 from $57 at Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
FATE Fate Therapeutics
$32.30 /

+4.05 (+14.34%)

  • 09
    Jun
FATE Fate Therapeutics
$32.30 /

+4.05 (+14.34%)

Syndicate
Fate Therapeutics 6.2M share Spot Secondary priced at $28.31 » 07:31
06/09/20
06/09
07:31
06/09/20
07:31
FATE

Fate Therapeutics

$28.25 /

+0.07 (+0.25%)

Jefferies, SVB Leerink,…

Jefferies, SVB Leerink, Barclays and Guggenheim acted as joint book running managers for the offering.

ShowHide Related Items >><<
FATE Fate Therapeutics
$28.25 /

+0.07 (+0.25%)

FATE Fate Therapeutics
$28.25 /

+0.07 (+0.25%)

05/13/20
Fly Intel: Top five analyst initiations
05/13/20 H.C. Wainwright
Fate Therapeutics initiated with a Buy at H.C. Wainwright
04/02/20 Piper Sandler
Fate Therapeutics price target raised to $63 from $57 at Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
FATE Fate Therapeutics
$28.25 /

+0.07 (+0.25%)

FATE Fate Therapeutics
$28.25 /

+0.07 (+0.25%)

Syndicate
Fate Therapeutics announces common stock offering, no amount given » 16:07
06/08/20
06/08
16:07
06/08/20
16:07
FATE

Fate Therapeutics

$28.30 /

+0.12 (+0.43%)

Fate Therapeutics…

Fate Therapeutics announced that it has commenced an underwritten public offering of its common stock. Fate Therapeutics intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies, the manufacture of its clinical product candidates, the expansion of its cGMP compliant manufacturing operations, including the construction, commissioning and qualification of its new facility, the conduct of preclinical research and development, and for general corporate purposes. Jefferies, SVB Leerink and Barclays are acting as joint book-running managers for the offering.

ShowHide Related Items >><<
FATE Fate Therapeutics
$28.30 /

+0.12 (+0.43%)

FATE Fate Therapeutics
$28.30 /

+0.12 (+0.43%)

05/13/20
Fly Intel: Top five analyst initiations
05/13/20 H.C. Wainwright
Fate Therapeutics initiated with a Buy at H.C. Wainwright
04/02/20 Piper Sandler
Fate Therapeutics price target raised to $63 from $57 at Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
FATE Fate Therapeutics
$28.30 /

+0.12 (+0.43%)

FATE Fate Therapeutics
$28.30 /

+0.12 (+0.43%)

Over a month ago
Hot Stocks
Fate Therapeutics announces FDA clearance of IND application for FT538 » 08:15
05/20/20
05/20
08:15
05/20/20
08:15
FATE

Fate Therapeutics

$28.85 /

-0.76 (-2.57%)

Fate Therapeutics…

Fate Therapeutics announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug application for FT538, the first CRISPR-edited, iPSC-derived cell therapy. FT538 is an off-the-shelf natural killer cell cancer immunotherapy that is derived from a clonal master induced pluripotent stem cell line engineered with three functional components to enhance innate immunity: a novel high-affinity, non-cleavable CD16 Fc receptor; an IL-15/IL-15 receptor fusion; and the elimination of CD38 expression. The Company plans to initiate clinical investigation of three once-weekly doses of FT538 as a monotherapy in acute myeloid leukemia and in combination with daratumumab, a CD38-directed monoclonal antibody therapy, for the treatment of multiple myeloma. The three functional components of FT538 are designed to boost the innate immune response in cancer patients, where endogenous NK cells are typically diminished in both number and function due to prior treatment regimens and tumor suppressive mechanisms. In preclinical studies, FT538 has shown superior NK cell effector function, as compared to endogenous NK cells, with the potential to confer significant anti-tumor activity to patients through multiple mechanisms of action including: Expression of the hnCD16 Fc receptor, which improves antibody-dependent cellular cytotoxicity, a potent anti-tumor mechanism by which NK cells recognize, bind and kill antibody-coated cancer cells; Expression of the IL-15RF cytokine complex, which promotes NK cell survival and persistence and induces trans-activation of endogenous NK cells and CD8 T cells; and Elimination of CD38 expression, which enhances innate effector function, including granzyme and perforin levels and resistance to oxidative stress, and prevents anti-CD38 antibody-mediated NK cell death. The first-in-human, multi-center, dose-escalation Phase 1 clinical trial of FT538 is designed to determine the maximum tolerated dose of three once-weekly doses of FT538 in up to 105 adult patients across four dose cohorts. The study will assess two treatment regimens: Regimen A as a monotherapy in patients with relapsed / refractory AML; and Regimen B in combination with daratumumab, an FDA-approved anti-CD38 monoclonal antibody, in patients with relapsed / refractory multiple myeloma who have failed at least two lines of therapy. In addition, the Company may initiate a third treatment regimen in combination with elotuzumab, an FDA-approved anti-SLAMF7 monoclonal antibody, in patients with relapsed / refractory multiple myeloma who have failed at least two lines of therapy starting at one dose level below the MTD of Regimen B. For all regimens, multiple indication- or dose-specific dose-expansion cohorts of up to 15 patients per cohort may be enrolled to further evaluate the clinical activity of FT538. FT538 is the fourth off-the-shelf, iPSC-derived NK cell product candidate from the Company's proprietary iPSC product platform cleared for clinical investigation by the FDA. The Company has initiated clinical manufacture of FT538 at its GMP facility in San Diego, CA.

ShowHide Related Items >><<
FATE Fate Therapeutics
$28.85 /

-0.76 (-2.57%)

FATE Fate Therapeutics
$28.85 /

-0.76 (-2.57%)

05/13/20
Fly Intel: Top five analyst initiations
05/13/20 H.C. Wainwright
Fate Therapeutics initiated with a Buy at H.C. Wainwright
04/02/20 Piper Sandler
Fate Therapeutics price target raised to $63 from $57 at Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
FATE Fate Therapeutics
$28.85 /

-0.76 (-2.57%)

FATE Fate Therapeutics
$28.85 /

-0.76 (-2.57%)

Initiation
Fly Intel: Top five analyst initiations » 10:05
05/13/20
05/13
10:05
05/13/20
10:05
WW

WW

$24.78 /

+1.3 (+5.54%)

, CGEN

Compugen

$15.40 /

+0.56 (+3.77%)

, CLSD

Clearside Biomedical

$2.25 /

+0.26 (+13.07%)

, FATE

Fate Therapeutics

$28.60 /

-0.08 (-0.28%)

, VTSI

VirTra

$2.25 /

-0.03 (-1.32%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. WW (WW) initiated with a Buy at Jefferies. 2. Compugen (CGEN) initiated with a Buy at Stifel. 3. Clearside Biomedical (CLSD) initiated with a Buy at Roth Capital. 4. Fate Therapeutics (FATE) initiated with a Buy at H.C. Wainwright. 5. VirTra (VTSI) resumed with a Buy at Roth Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
WW WW
$24.78 /

+1.3 (+5.54%)

VTSI VirTra
$2.25 /

-0.03 (-1.32%)

FATE Fate Therapeutics
$28.60 /

-0.08 (-0.28%)

CLSD Clearside Biomedical
$2.25 /

+0.26 (+13.07%)

CGEN Compugen
$15.40 /

+0.56 (+3.77%)

WW WW
$24.78 /

+1.3 (+5.54%)

05/12/20 Jefferies
WW initiated with a Buy at Jefferies
05/12/20 Jefferies
WW initiated with a Buy at Jefferies
04/29/20 SunTrust
WW price target raised to $26 from $13 at SunTrust
04/29/20 B. Riley FBR
WW price target raised to $30 from $28 at B. Riley FBR
CGEN Compugen
$15.40 /

+0.56 (+3.77%)

05/13/20 Stifel
Compugen initiated with a Buy at Stifel
05/07/20
Fly Intel: Top five analyst initiations
05/07/20 SVB Leerink
Compugen initiated with an Outperform at SVB Leerink
04/28/20 SunTrust
Compugen price target raised to $22 from $16 at SunTrust
CLSD Clearside Biomedical
$2.25 /

+0.26 (+13.07%)

05/13/20 Roth Capital
Clearside Biomedical initiated with a Buy at Roth Capital
12/17/19 JMP Securities
FDA to accept RVO clinial use data from Clearside, says JMP Securities
10/14/19 Roth Capital
Ophthalmic therapies 'could go from 0 to 100 real quick,' says Roth Capital
08/22/19 JMP Securities
Clearside Biomedical price target lowered to $3 from $4 at JMP Securities
FATE Fate Therapeutics
$28.60 /

-0.08 (-0.28%)

05/13/20 H.C. Wainwright
Fate Therapeutics initiated with a Buy at H.C. Wainwright
04/02/20 Piper Sandler
Fate Therapeutics price target raised to $63 from $57 at Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Citi
Fate Therapeutics price target raised to $41 from $26 at Citi
VTSI VirTra
$2.25 /

-0.03 (-1.32%)

05/13/20 Roth Capital
VirTra resumed with a Buy at Roth Capital
08/14/19 Lake Street
VirTra price target lowered to $5 from $6 at Lake Street
05/28/19 Roth Capital
VirTra initiated with a Buy at Roth Capital
WW WW
$24.78 /

+1.3 (+5.54%)

VTSI VirTra
$2.25 /

-0.03 (-1.32%)

FATE Fate Therapeutics
$28.60 /

-0.08 (-0.28%)

CLSD Clearside Biomedical
$2.25 /

+0.26 (+13.07%)

CGEN Compugen
$15.40 /

+0.56 (+3.77%)

WW WW
$24.78 /

+1.3 (+5.54%)

FATE Fate Therapeutics
$28.60 /

-0.08 (-0.28%)

WW WW
$24.78 /

+1.3 (+5.54%)

Initiation
Fate Therapeutics initiated with a Buy at H.C. Wainwright » 07:24
05/13/20
05/13
07:24
05/13/20
07:24
FATE

Fate Therapeutics

$28.68 /

-1.62 (-5.35%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Debjit Chattopadhyay initiated coverage of Fate Therapeutics with a Buy rating and $42 price target. The analyst believes FT596 is "poised to build upon the early and promising experience of cord blood NK CARs." Given the surge of interest in the space, and the "plethora" of Fate's clinical milestones, "there is headroom for the stock," Chattopadhyay tells investors in a research note.

ShowHide Related Items >><<
FATE Fate Therapeutics
$28.68 /

-1.62 (-5.35%)

FATE Fate Therapeutics
$28.68 /

-1.62 (-5.35%)

04/02/20 Piper Sandler
Fate Therapeutics price target raised to $63 from $57 at Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Citi
Fate Therapeutics price target raised to $41 from $26 at Citi
03/04/20 Barclays
Fate Therapeutics initiated with an Overweight at Barclays
FATE Fate Therapeutics
$28.68 /

-1.62 (-5.35%)

FATE Fate Therapeutics
$28.68 /

-1.62 (-5.35%)

On The Fly
Fly Intel: After-Hours Movers » 19:08
05/11/20
05/11
19:08
05/11/20
19:08
CBAY

CymaBay

$1.84 /

+0.045 (+2.51%)

, IIVI

II-VI

$36.29 /

+0.45 (+1.26%)

, VRRM

Verra Mobility

$9.12 /

+0.08 (+0.88%)

, SGRY

Surgery Partners

$10.82 /

-0.12 (-1.10%)

, GDOT

Green Dot

$30.78 /

-0.73 (-2.32%)

, GO

Grocery Outlet

$36.71 /

+0.01 (+0.03%)

, CZR

Caesars

$9.65 /

-0.06 (-0.62%)

, NVAX

Novavax

$24.59 /

+5.86 (+31.29%)

, AMC

AMC Entertainment

$5.32 /

+1.225 (+29.91%)

, EB

Eventbrite

$10.51 /

+0.26 (+2.54%)

, DIOD

Diodes

$50.09 /

-0.31 (-0.62%)

, ICAD

iCAD

$12.31 /

-0.55 (-4.28%)

, TLRY

Tilray

$8.09 /

+0.305 (+3.92%)

, TME

Tencent Music

$11.43 /

+0.39 (+3.53%)

, AIMT

Aimmune

$17.89 /

+0.28 (+1.59%)

, SGMO

Sangamo

$9.08 /

+0.4 (+4.61%)

, HALO

Halozyme

$24.82 /

+1.24 (+5.26%)

, FATE

Fate Therapeutics

$30.30 /

+1.45 (+5.03%)

, PLYA

Playa Hotels & Resorts

$2.11 /

+0.06 (+2.93%)

, JCOM

j2 Global

$81.40 /

+0.03 (+0.04%)

, SGMS

Scientific Games

$12.97 /

-0.18 (-1.37%)

, MAXR

Maxar Technologies

$11.61 /

+0.37 (+3.29%)

, FSCT

ForeScout

$32.12 /

-0.08 (-0.25%)

, OMER

Omeros

$17.01 /

+0.99 (+6.18%)

, SCPL

SciPlay

$12.22 /

+0.33 (+2.78%)

, HTZ

Hertz

$3.18 /

-0.07 (-2.15%)

, AKBA

Akebia

$12.85 /

+0.86 (+7.17%)

, QTWO

Q2 Holdings

$81.58 /

-1.04 (-1.26%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
CBAY CymaBay
$1.84 /

+0.045 (+2.51%)

03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
03/13/20 Oppenheimer
CymaBay upgraded to Outperform from Perform at Oppenheimer
03/13/20 Cantor Fitzgerald
CymaBay upgraded to Overweight from Neutral at Cantor Fitzgerald
02/26/20 Citi
Citi upgrades Intercept to Buy on peak sales potential of Ocaliva
IIVI II-VI
$36.29 /

+0.45 (+1.26%)

03/23/20
Fly Intel: Top analyst initiations
03/23/20 Barclays
Barclays starts II-VI with Overweight rating, $31 price target
03/23/20 Barclays
II-VI initiated with an Overweight at Barclays
03/20/20 Craig-Hallum
II-VI price target lowered to $35 from $45 at Craig-Hallum
VRRM Verra Mobility
$9.12 /

+0.08 (+0.88%)

04/29/20 Credit Suisse
Verra Mobility price target lowered to $10.50 from $17 at Credit Suisse
03/18/20 Deutsche Bank
Verra Mobility price target lowered to $12 from $18 at Deutsche Bank
01/24/20 Credit Suisse
Credit Suisse sees more M&A in 2020 for FinTechs, processors and payments
01/23/20 Credit Suisse
Verra Mobility initiated with an Outperform at Credit Suisse
SGRY Surgery Partners
$10.82 /

-0.12 (-1.10%)

04/27/20 Benchmark
Surgery Partners upgraded to Buy on faster recovery timeline at Benchmark
04/27/20 Benchmark
Surgery Partners upgraded to Buy from Hold at Benchmark
04/21/20
Envision bankruptcy report has limited read-throughs, says Benchmark
03/24/20 RBC Capital
Surgery Partners price target lowered to $14 from $19 at RBC Capital
GDOT Green Dot
$30.78 /

-0.73 (-2.32%)

04/07/20 Craig-Hallum
Green Dot assumed with a Buy at Craig-Hallum
03/26/20 SunTrust
Green Dot price target lowered to $40 from $48 at SunTrust
03/26/20 BTIG
BTIG upgrades Green Dot to Buy on 'game-changer' CEO hire
03/25/20 BTIG
Green Dot upgraded to Buy from Neutral at BTIG
GO Grocery Outlet
$36.71 /

+0.01 (+0.03%)

01/29/20
Fly Intel: Top five analyst initiations
01/29/20 Craig-Hallum
Grocery Outlet initiated with a Buy at Craig-Hallum
11/12/19 Jefferies
Grocery Outlet comps remain well above industry trend, says Jefferies
08/14/19 Jefferies
Grocery Outlet price target raised to $50 from $41 at Jefferies
CZR Caesars
$9.65 /

-0.06 (-0.62%)

04/17/20 SunTrust
Caesars, Twin River Worldwide upgraded to Buy from Hold at SunTrust
04/17/20 SunTrust
Caesars upgraded to Buy from Hold at SunTrust
04/06/20 Jefferies
Eldorado has 'considerable upside' from Caesars merger, says Jefferies
04/03/20 Stifel
Eldorado Resorts shares offer 250% upside from current levels, says Stifel
NVAX Novavax
$24.59 /

+5.86 (+31.29%)

04/30/20 H.C. Wainwright
Novavax price target raised to $33 from $24 at H.C. Wainwright
04/24/20 B. Riley FBR
Novavax price target raised to $29 from $20 at B. Riley FBR
04/09/20 Ladenburg
Ladenburg ups Novavax target to $28 on 'potent' COVID vaccine candidate
03/27/20 B. Riley FBR
Novavax price target raised to $20 from $15 at B. Riley FBR
AMC AMC Entertainment
$5.32 /

+1.225 (+29.91%)

05/11/20 B. Riley FBR
Amazon buyout may not appeal to AMC shareholders, says B. Riley FBR
04/30/20 Imperial Capital
AMC Entertainment price target raised to $3 from $2 at Imperial Capital
04/23/20 Macquarie
AMC Entertainment downgraded to Neutral from Outperform at Macquarie
04/22/20 JPMorgan
JPMorgan downgrades EPR after only15% of April rents get collected
EB Eventbrite
$10.51 /

+0.26 (+2.54%)

04/03/20 SunTrust
Eventbrite price target lowered to $8 from $19 at SunTrust
02/28/20 SunTrust
Eventbrite price target lowered to $19 from $22 at SunTrust
02/28/20 RBC Capital
Eventbrite downgraded to Sector Perform from Outperform at RBC Capital
01/24/20 William Blair
Data shows Eventbrite fan engagement is growing, says William Blair
DIOD Diodes
$50.09 /

-0.31 (-0.62%)

04/17/20 Baird
Diodes upgraded to Outperform at Baird
04/17/20 Baird
Diodes upgraded to Outperform from Neutral at Baird
03/19/20 Wells Fargo
Diodes price target lowered to $55 from $64 at Wells Fargo
02/10/20 Baird
Baird removes 'Fresh Pick Designation' on Diodes for China disruptions
ICAD iCAD
$12.31 /

-0.55 (-4.28%)

02/13/20 Craig-Hallum
iCAD price target raised to $15 from $9 at Craig-Hallum
02/05/20 JMP Securities
iCAD initiated with an Outperform at JMP Securities
01/09/20 Lake Street
Lake Street starts 'disruptive' iCAD with Buy rating, $14 price target
12/20/19
iCAD initiated with a Buy at Dougherty
TLRY Tilray
$8.09 /

+0.305 (+3.92%)

04/16/20 Jefferies
Tilray downgraded to Underperform following 'short squeeze' at Jefferies
04/16/20 Jefferies
Tilray downgraded to Underperform from Hold at Jefferies
04/09/20 Consumer Edge
Tilray downgraded to Equal Weight from Overweight at Consumer Edge
04/08/20 Raymond James
Ontario AG order positive for Canadian cannabis stocks, says Raymond James
TME Tencent Music
$11.43 /

+0.39 (+3.53%)

03/18/20 BOCOM
Tencent Music upgraded to Neutral from Sell at BOCOM
03/12/20 Morgan Stanley
Tencent Music upgraded to Overweight from Equal Weight at Morgan Stanley
02/25/20 Goldman Sachs
Huya downgraded to Neutral on cost inflation at Goldman Sachs
02/19/20
Fly Intel: Top five analyst downgrades
AIMT Aimmune
$17.89 /

+0.28 (+1.59%)

04/06/20 Citi
DBV's Viaskin Peanut more likely than not to be approved, says Citi
04/06/20 Piper Sandler
Aimmune launch 'thrown a wrench' amid COVID-19, says Piper Sandler
03/23/20 Cantor Fitzgerald
Aimmune price target lowered to $32 from $64 at Cantor Fitzgerald
03/18/20 JMP Securities
Aimmune downgraded to Market Perform from Outperform at JMP Securities
SGMO Sangamo
$9.08 /

+0.4 (+4.61%)

02/28/20 William Blair
Biogen deal with Sangamo unlikely to have near-term impact, says William Blair
02/03/20 Evercore ISI
Evercore ISI downgrades Crispr Therapeutics, questions relative valuation
08/26/19
Fly Intel: Top five analyst initiations
08/26/19 H.C. Wainwright
Sangamo initiated with a Buy at H.C. Wainwright
HALO Halozyme
$24.82 /

+1.24 (+5.26%)

05/04/20 Cantor Fitzgerald
Halozyme price target raised to $39 from $35 at Cantor Fitzgerald
02/05/20
Fly Intel: Top five analyst upgrades
02/05/20 Piper Sandler
Halozyme upgraded to Overweight from Neutral at Piper Sandler
FATE Fate Therapeutics
$30.30 /

+1.45 (+5.03%)

04/02/20 Piper Sandler
Fate Therapeutics price target raised to $63 from $57 at Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Citi
Fate Therapeutics price target raised to $41 from $26 at Citi
03/04/20 Barclays
Fate Therapeutics initiated with an Overweight at Barclays
PLYA Playa Hotels & Resorts
$2.11 /

+0.06 (+2.93%)

04/29/20 SunTrust
Playa Hotels & Resorts downgraded to Hold from Buy at SunTrust
04/29/20 SunTrust
Playa Hotels & Resorts downgraded to Hold from Buy at SunTrust
04/07/20 Citi
Playa Hotels & Resorts downgraded to Sell from Neutral at Citi
04/03/20 Deutsche Bank
Playa Hotels & Resorts price target lowered to $7 from $11 at Deutsche Bank
JCOM j2 Global
$81.40 /

+0.03 (+0.04%)

04/29/20
Fly Intel: Top five analyst initiations
04/29/20 JPMorgan
j2 Global initiated with an Overweight, $105 target at JPMorgan
04/29/20 JPMorgan
j2 Global initiated with an Overweight at JPMorgan
04/02/20
Fly Intel: Top five analyst initiations
SGMS Scientific Games
$12.97 /

-0.18 (-1.37%)

04/16/20 Jefferies
Gaming equipment suppliers 'managing around' fortunes of casinos, says Jefferies
04/15/20 Craig-Hallum
Scientific Games price target lowered to $20 from $55 at Craig-Hallum
02/20/20 Deutsche Bank
Scientific Games price target lowered to $23 from $29 at Deutsche Bank
02/19/20 Craig-Hallum
Scientific Games price target lowered to $55 from $60 at Craig-Hallum
MAXR Maxar Technologies
$11.61 /

+0.37 (+3.29%)

01/15/20 Credit Suisse
Maxar Technologies upgraded to Neutral from Underperform at Credit Suisse
01/08/20 JPMorgan
Maxar Technologies price target raised to $25 from $15 at JPMorgan
12/30/19 Raymond James
Maxar Technologies downgraded to Market Perform from Outperform at Raymond James
12/19/19 CIBC
Maxar Technologies upgraded to Neutral from Underperformer at CIBC
FSCT ForeScout
$32.12 /

-0.08 (-0.25%)

02/18/20 Baird
ForeScout acquired, Baird downgrades to Neutral
02/18/20 Baird
ForeScout downgraded to Neutral from Outperform at Baird
02/07/20 Berenberg
ForeScout downgraded to Hold from Buy at Berenberg
02/07/20 Monness Crespi
ForeScout downgraded to Neutral from Buy at Monness Crespi
OMER Omeros
$17.01 /

+0.99 (+6.18%)

03/04/20 Wedbush
Omeros price target raised to $22 from $18 at Wedbush
03/03/20 Cantor Fitzgerald
Omeros shares can 'significantly rerate' from here, says Cantor Fitzgerald
11/05/19 H.C. Wainwright
Omeros recent selloff appears unwarranted, says H.C. Wainwright
SCPL SciPlay
$12.22 /

+0.33 (+2.78%)

04/22/20 BofA
SciPlay upgraded to Neutral from Underperform at BofA
04/22/20 BofA
SciPlay upgraded to Neutral from Underperform at BofA
04/17/20 SunTrust
SciPlay upgraded to Buy at SunTrust as a 'stay-at-home play'
04/17/20 SunTrust
SciPlay upgraded to Buy from Hold at SunTrust
HTZ Hertz
$3.18 /

-0.07 (-2.15%)

05/05/20 Morgan Stanley
2020 may not be quite as bad as feared for used cars, says Morgan Stanley
04/27/20
Fly Intel: Top five analyst downgrades
04/27/20 Barclays
Barclays downgrades Hertz to Underweight on risk of capital call
04/27/20 Barclays
Hertz downgraded to Underweight from Equal Weight at Barclays
AKBA Akebia
$12.85 /

+0.86 (+7.17%)

05/06/20 RBC Capital
Akebia price target raised to $12 from $8 at RBC Capital
05/05/20 Piper Sandler
Piper Sandler remains a buyer of Akebia following Phase 3 INNO2VATE data
05/05/20 Piper Sandler
Piper says efficacy, safety of FibroGen, Akebia drugs 'quite similar' in DD-CKD
05/05/20 Piper Sandler
Piper sees Akebia shares having 'nice follow through' on pre-market upside
QTWO Q2 Holdings
$81.58 /

-1.04 (-1.26%)

05/08/20 RBC Capital
Q2 Holdings price target raised to $92 from $73 at RBC Capital
04/29/20
Fly Intel: Top five analyst upgrades
04/29/20 Baird
Q2 Holdings upgraded to Outperform at Baird
04/29/20 Baird
Q2 Holdings upgraded to Outperform from Neutral at Baird
  • 13
    May
  • 12
    May
Earnings
Fate Therapeutics reports Q1 EPS (44c), consensus (39c) » 16:05
05/11/20
05/11
16:05
05/11/20
16:05
FATE

Fate Therapeutics

$29.83 /

+0.98 (+3.40%)

Reports Q1 revenue…

Reports Q1 revenue $2.52M, consensus $1.8M. "We are encouraged by the resilience of our employees, our clinical trial investigators and participating patients, and our collaboration partners in the face of the challenge posed by the global pandemic. Like others, we have been affected by COVID-19, which has impacted clinical site initiation, slowed the cadence of new patient enrollment, and changed how we conduct our day-to-day business," said Scott Wolchko, President and CEO of Fate Therapeutics. "Nevertheless, we have continued to enroll patients across our three Phase 1 clinical programs, expanded the clinical footprint of our FT596 program into relapse prevention following autologous HSCT, and submitted our IND application to the FDA for FT538, the first-ever CRISPR-edited, iPSC-derived cell therapy, in multiple myeloma. Additionally, we entered into a transformative collaboration with Janssen that leverages our iPSC product platform and Janssen's proprietary tumor-targeting antigen binders to develop novel CAR NK and CAR T-Cell product candidates for hematologic malignancies and solid tumors, supporting our fundamental goal of bringing off-the-shelf, iPSC-derived cell-based cancer immunotherapies to patients."

ShowHide Related Items >><<
FATE Fate Therapeutics
$29.83 /

+0.98 (+3.40%)

04/02/20 Piper Sandler
Fate Therapeutics price target raised to $63 from $57 at Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Citi
Fate Therapeutics price target raised to $41 from $26 at Citi
03/04/20 Barclays
Fate Therapeutics initiated with an Overweight at Barclays
Hot Stocks
Fate Therapeutics to present cell-based cancer immunotherapy program data » 16:46
04/28/20
04/28
16:46
04/28/20
16:46
FATE

Fate Therapeutics

$27.94 /

-2.27 (-7.51%)

Fate Therapeutics…

Fate Therapeutics announced the presentation of a new off-the-shelf, iPSC-derived, chimeric antigen receptor, or CAR-targeted, cell-based cancer immunotherapy program at the American Society of Gene & Cell Therapy. The new preclinical program targets MHC class I related proteins A, or MICA, and , or MICB, and is supported by an exclusive license from the Dana-Farber Cancer Institute to intellectual property covering novel antibody fragments binding MICA/B for iPSC-derived cellular therapeutics. MICA and MICB are stress proteins that are selectively expressed at high levels on many solid tumors. While it is well known that tumor resistance to cytotoxic T cells is mediated by loss of MHC Class I expression, proteolytic shedding of the a1 and a2 domains of MICA/B expressed on tumor cells is a common mechanism of NK cell evasion. A recent publication in Science, demonstrated that antibody targeting of the MICA/B a3 domains specifically prevents MICA/B shedding and restores NK cell-mediated immunity. Additionally, in a more recent publication in Cancer Immunology Research, it was demonstrated that cancers with B2M and JAK1 inactivating mutations resulting in loss of MHC Class I expression can be effectively targeted with MICA/B a3 domain-specific antibodies to restore NK cell-mediated immunity against solid tumors resistant to cytotoxic T cells. Using a clonal master induced pluripotent stem cell, or iPSC, line previously engineered with an expression cassette introduced into the CD38 locus that encodes for a high-affinity, non-cleavable CD16 Fc receptor and an IL-15 receptor fusion, scientists from Fate Therapeutics introduced a second expression cassette encoding for the novel CAR MICA/B construct. In vitro differentiation of the clonal iPSC lines produced homogeneous NK cell populations with uniform expression of CAR MICA/B, hnCD16, and IL15RF, and without any expression of CD38. The iPSC-derived CAR NK cells displayed enhanced cytokine production and cytotoxicity against MICA/B positive tumor cells compared to non-engineered, iPSC-derived NK cells.

ShowHide Related Items >><<
FATE Fate Therapeutics
$27.94 /

-2.27 (-7.51%)

04/02/20 Piper Sandler
Fate Therapeutics price target raised to $63 from $57 at Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Citi
Fate Therapeutics price target raised to $41 from $26 at Citi
03/04/20 Barclays
Fate Therapeutics initiated with an Overweight at Barclays

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.